Evidence map›Paper›PMID 28741166›Full record

ArticleAngiogenesis2017

A new key player in VEGF-dependent angiogenesis in human hepatocellular carcinoma: dimethylarginine dimethylaminohydrolase 1.

Nikki Buijs, J Efraim Oosterink, Morgan Jessup, Henk Schierbeek, Donna B Stolz, Alexander P Houdijk, David A Geller, Paul A van Leeuwen

Open access · hybridAbstract read
In one paragraph

Article in Angiogenesis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 70 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. NO and hepatocellular cancer.British journal of pharmacology · 2020
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Nikki BuijsDepartment of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. n.buijs@vumc.nl.ORCID http://orcid.org/0000-0002-0256-9597
J Efraim OosterinkDepartment of Pediatrics, Academic Medical Center, Emma Children's Hospital, Amsterdam, The Netherlands.
Morgan JessupDepartment of Cell Biology and Physiology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Henk SchierbeekDepartment of Pediatrics, Academic Medical Center, Emma Children's Hospital, Amsterdam, The Netherlands.
Donna B StolzDepartment of Cell Biology and Physiology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Alexander P HoudijkDepartment of Surgery, Medical Center Alkmaar, Trial Center Holland Health, Alkmaar, The Netherlands.
David A GellerDepartment of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Paul A van LeeuwenDepartment of Surgery, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.
University of Pittsburgh Medical Center · USAmsterdam UMC Location University of Amsterdam · NLAmsterdam UMC Location Vrije Universiteit Amsterdam · NLMedisch Centrum Alkmaar · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnti-angiogenic therapies, targeting VEGF, are a promising treatment for hepatocellular carcinoma (HCC). To enhance this potential therapy, identification of novel targets in this pathway is of major interest. Nitric oxide (NO) plays a crucial role in VEGF-dependent angiogenesis. NO production depends on arginine as substrate and asymmetric dimethylarginine (ADMA) as inhibitor. Dimethylarginine dimethylaminohydrolase 1 (DDAH-1) catabolizes ADMA and therefore regulates NO and VEGF expression. This study unravels additional mechanisms to improve VEGF targeting therapies.

methodsThe expression of DDAH-1 was examined in HCC specimen and non-tumorous background liver of 20 patients undergoing liver resection. Subsequently, arginine/ADMA balance, NO production, and VEGF expression were analyzed. The influence of hypoxia on DDAH-1 and angiogenesis promoting factors was evaluated in HepG2 cells and primary human hepatocytes.

resultsDDAH-1 expression was significantly induced in primary HCC tumors compared to non-tumorous background liver. This was associated with an increased arginine/ADMA ratio, higher NO formation, and higher VEGF expression in human HCC compared to non-tumorous liver. Hypoxia induced DDAH-1, iNOS, and VEGF expression in a time-dependent manner in HepG2 cells.

conclusionsOur results indicate that DDAH-1 expression is increased in human HCC, which is associated with an increase in the arginine/ADMA ratio and enhanced NO formation. Hypoxia may be an initiating factor for the increase in DDAH-1 expression. DDAH-1 expression is associated with promotion of angiogenesis stimulating factor VEGF. Together, our findings for the first time identified DDAH-1 as a key player in the regulation of angiogenesis in human HCC, and by understanding this mechanism, future therapeutic strategies targeting VEGF can be improved.

Indexed as

AgedAmidohydrolasesArginineCarcinoma, HepatocellularCell HypoxiaFemaleHep G2 CellsHumansLiver NeoplasmsMaleNeovascularization, PathologicNitric OxideNitric Oxide Synthase Type IIVascular Endothelial Growth Factor AAmidohydrolasesArgininedimethylargininaseNitric OxideNitric Oxide Synthase Type IIN,N-dimethylarginineVascular Endothelial Growth Factor AAngiogenesisArginineAsymmetric dimethylarginineDimethylarginine dimethylaminohydrolaseHepatocellular carcinomaHypoxiaNitric oxideVEGF

Identifiers

PMID28741166
PMCPMC5660142
OpenAlexW2738744058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.